Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07249320 · ClinicalTrials.gov registry record
Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants
A clinical trial of Respiratory Syncytial Virus (RSV), sponsored by Pfizer.
- Active
- Registry status
- 39,456
- Enrollment target
- 1
- Study location
NCT07249320: Active study of Respiratory Syncytial Virus (RSV), sponsored by Pfizer.
NCT07249320 is a study of Respiratory Syncytial Virus (RSV) that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 39,456 participants, above the 3,169-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (1145% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07249320, a study of Respiratory Syncytial Virus (RSV), is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- 39,456 participants
- Enrollment target
- 1
- Study location
Study Summary
To generate critical evidence to support vaccine policy and implementation, Pfizer will collaborate with Kaiser Permanente Northern California (KPNC) to study the vaccine effectiveness (VE) of ABRYSVO vaccination during pregnancy in a real-world population. The overall research question of this study is: what is the effectiveness of ABRYSVO vaccination during pregnancy against medically-attended (MA) RSV-associated and all-cause infant outcomes in a large, diverse, real-world population? This study will use a retrospective cohort design and will be conducted within an integrated delivery health care organization using electronic medical record (EMR) data collected during routine standard of care clinical encounters. Study outcomes among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later assessments from birth through 12 months of age and through 24 months of age as the infants reach these age thresholds and their data become available. There are two categories of outcomes of interest in this study: RSV-specific infant outcomes and non-specific all-cause infant outcomes, assessed within several follow-up windows (birth through 6 months of age, birth through 12 months of age, and/or birth through 24 months of age, depending on the outcome). Identification of RSV-specific outcomes will be based on the first positive laboratory-confirmed PCR test from a respiratory specimen during a healthcare encounter in a KPNC healthcare setting, occurring during the relevant follow-up window. RSV-positive test results will be combined with International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to define the RSV-specific outcomes. RSV-specific outcomes will include: PCR-confirmed RSV, PCR-confirmed RSV hospitalization, PCR-confirmed RSV LRTD, and PCR-confirmed RSV LRTD
Primary Outcome
To estimate VE of ABRYSVO vaccination during pregnancy against RSV LRTD among infants from birth to ≤180 days of age.
Conditions Studied
Interventions
- BIOLOGICAL ABRYSVO
Study Locations (1)
New York
- Pfizer - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39,456 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-09-30 |
What the registry record for NCT07249320 still lists
NCT07249320 is an observational study that tracks outcomes without assigning an intervention. Its 39,456 participants enrollment target places it among the larger protocols in the corpus, above the 3,169-participant average among 11 other Respiratory Syncytial Virus (RSV) trials with a reported enrollment target (1145% higher).
The record links to 1 condition, with Respiratory Syncytial Virus (RSV) appearing as the primary indexed condition, and to 1 intervention - of which ABRYSVO is the first listed.
NCT07249320 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07249320 about?
NCT07249320 is a clinical study titled "Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants". To generate critical evidence to support vaccine policy and implementation, Pfizer will collaborate with Kaiser Permanente Northern California (KPNC) to study the vaccine effectiveness (VE) of ABRYSVO vaccination during pregnancy in a real-world population. The overall research question of this stud...
What is the current status of trial NCT07249320?
This trial is currently active not recruiting. The enrollment target is 39,456 participants. The study started on 2025-12-01. Estimated completion is 2027-09-30.
What conditions does trial NCT07249320 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus (RSV).
What interventions are being tested in trial NCT07249320?
The interventions under investigation include: ABRYSVO (BIOLOGICAL).
Who is sponsoring clinical trial NCT07249320?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07249320 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus (RSV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07249320's enrollment target sits among peer trials
39,456 1st of 11 higher than 11 of 11 other Respiratory Syncytial Virus (RSV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Syncytial Virus (RSV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RSV Vaccine Pregnancy Registry
RECRUITING
-
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
RECRUITING · Phase 2
-
Systems Biological Analysis of Immune Responses to RSV Vaccine
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV
ACTIVE NOT RECRUITING · Phase 1
-
Transplacental Transmission of RSV (TTRSV)
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01255748 · 40,000 participants
Registry Study for Radiation Therapy Outcomes
- NCT04994756 · 40,000 participants
Stroke Thrombectomy and Aneurysm Registry
- NCT06768814 · 40,000 participants · NA
Overdose Recovery and Care Access (ORCA) Qualitative Stakeholder Interviews and County-level Data
- NCT07109427 · 40,000 participants · NA
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI